'Been through a lot': New Passage Bio CEO talks about 'rising tide'; Back in business with the FDA, BioMarin finds itself without a CMO
Chou himself recently departed another gene therapy developer that has essentially shuttered. Aruvant, from the Roivant web, ceased clinical development of a lentiviral gene therapy for beta thalassemia after enrolling seven patients, and a preclinical AAV gene therapy for patients with hypophosphatasia, the parent company announced this summer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.